Nexstim Plc

Nexstim Plc manufactures navigated transcranial magnetic stimulation (nTMS) and repetitive TMS (rTMS) systems for clinical diagnosis, surgical planning, and therapeutic applications. The company's primary products are the SmartFocus® nTMS and NBS System platforms, which use 3D imaging and image-guided navigation to precisely target and quantify the electric field dose delivered to the brain. Clinical applications include motor and language mapping for presurgical planning in neurosurgery and epilepsy, treatment of major depressive disorder (FDA cleared), obsessive-compulsive disorder (OCD; FDA cleared as of 2026), and post-operative rehabilitation for spinal cord injury and complex regional pain syndrome (CRPS). The systems are used in academic medical centers, children's hospitals, and specialized neurosurgery and psychiatry clinics worldwide. Nexstim holds FDA 510(k) clearances and CE/MDR certification for multiple therapeutic indications. The company serves neurosurgeons, neuroradiologists, epileptologists, psychiatrists, and rehabilitation specialists. The technology integrates real-time neurophysiological feedback (motor evoked potentials, MEP recording) with anatomical imaging to guide clinical decision-making and optimize patient outcomes.